Viberzi is a prescription medication approved for treating irritable bowel syndrome with diarrhea (IBS-D) in adults. It works by acting on opioid receptors in the gut to slow down bowel activity, reduce abdominal pain, and firm up loose stools. Unlike general anti-diarrheal drugs, Viberzi was specifically designed and tested for IBS-D, targeting both the pain and the urgency that define the condition.
How Viberzi Works in IBS-D
IBS-D involves a combination of chronic abdominal pain and frequent loose or watery stools. Viberzi targets receptors in the digestive tract that influence how quickly food moves through the intestines and how pain signals are transmitted. By slowing gut motility and dampening pain signaling locally, it addresses the two core symptoms at once rather than treating them separately.
Because it acts on opioid receptors, Viberzi is classified as a Schedule IV controlled substance, meaning it has a low but real potential for dependence. In practice, this means your pharmacy may handle it differently than a standard prescription, and refills may require a new prescription depending on your state’s rules.
How Well It Works
Viberzi was tested in two large Phase 3 trials that together enrolled thousands of adults with IBS-D. To count as a “responder,” patients had to achieve at least a 30% reduction in their worst daily abdominal pain and reach a firmer stool consistency on at least half the days over 12 weeks. That’s a high bar, since it requires simultaneous improvement in both symptoms on most days.
In the first trial, 25.1% of patients on the standard dose met that threshold compared to 17.1% on placebo. In the second trial, the gap was wider: 29.6% on the standard dose versus 16.2% on placebo. These numbers may look modest at first glance, but the composite endpoint was strict. Many more patients experienced partial improvement in either pain or stool consistency without meeting the full responder definition.
The lower dose performed similarly, with response rates of about 24% to 29% across both studies. This gives prescribers flexibility to start patients at a lower dose without sacrificing much effectiveness.
Dosing and How to Take It
The standard dose is 100 mg taken twice daily with food. Some patients, particularly those 65 or older or those with certain medical considerations, may be started on 75 mg twice daily instead. Taking it with food is important, not optional.
If you miss a dose by more than four hours, skip it entirely and take the next one at your regular time. Do not double up.
The Gallbladder Warning
The most serious safety concern with Viberzi involves pancreatitis, and the risk is sharply concentrated in people who have had their gallbladder removed. A European safety review identified 230 reported cases of pancreatitis in patients taking the drug. Among the cases where gallbladder status was known, 76% occurred in patients without a gallbladder. Some of these cases led to hospitalization, and two contributed to patient deaths.
Because of this, Viberzi is now contraindicated in anyone who has had a cholecystectomy (gallbladder removal). It’s also off-limits for people with known or suspected blockages in the bile ducts or pancreatic duct, including from gallstones or tumors. If you’ve had your gallbladder removed, this medication is not an option for you, full stop.
Other People Who Should Not Take It
Beyond the gallbladder restriction, several other groups cannot safely use Viberzi:
- Heavy alcohol use. People who drink more than three alcoholic beverages per day, or who have a history of alcoholism or alcohol addiction, face an elevated risk of acute pancreatitis on this medication.
- Severe liver disease. Patients with severe hepatic impairment process the drug much more slowly, leading to dangerously high blood levels.
- Chronic or severe constipation. Because Viberzi slows the gut, anyone with a history of significant constipation or mechanical bowel obstruction could develop serious complications.
These aren’t just cautions. They are absolute contraindications listed on the FDA label, meaning the drug should not be prescribed under these circumstances.
What to Expect When Starting
Constipation is the most common side effect, which makes sense given that the drug’s entire purpose is to slow bowel activity. Nausea and abdominal pain can also occur, particularly in the first few weeks. Most people who tolerate the medication well in the first month continue without major issues.
If you develop new or worsening abdominal pain, especially pain that radiates to your back, or if you notice your skin or eyes turning yellow, those are signals to stop taking the medication and contact your doctor promptly. These could indicate pancreatitis or a problem with bile flow, both of which require immediate evaluation.
Viberzi is not a cure for IBS-D. It manages symptoms for as long as you take it, and symptoms typically return once you stop. Many people use it alongside dietary changes and other strategies as part of a broader approach to managing IBS-D over time.